NO20074610L - Fremgangsmate for a bestemme mottakeligheten til CHK1 inhibitorer - Google Patents

Fremgangsmate for a bestemme mottakeligheten til CHK1 inhibitorer

Info

Publication number
NO20074610L
NO20074610L NO20074610A NO20074610A NO20074610L NO 20074610 L NO20074610 L NO 20074610L NO 20074610 A NO20074610 A NO 20074610A NO 20074610 A NO20074610 A NO 20074610A NO 20074610 L NO20074610 L NO 20074610L
Authority
NO
Norway
Prior art keywords
chk1
patient
determining susceptibility
chk1 inhibitors
signal transmission
Prior art date
Application number
NO20074610A
Other languages
English (en)
Inventor
Sonya Zabluoff
Louise Bergeron
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20074610L publication Critical patent/NO20074610L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Oppfinnelsen er rettet mot en fremgangsmåte for å forutsi en pasients følsomhet overfor en CHK1-inhibitor. Fremgangsmåten inkluderer å skaffe en prøve fra en testpasient som er blitt behandlet med et DNA skadevirkemiddel; å bestemme for nærværet av et aktivert CHK1-signaloverføringsveimolekyl, karakterisert ved at nærværet av et aktivert CHK1-signaloverføringsveimolekyl er indikativt på at en CHK1-inhibitor bør bli administrert til pasienten.
NO20074610A 2005-02-18 2007-09-11 Fremgangsmate for a bestemme mottakeligheten til CHK1 inhibitorer NO20074610L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65413105P 2005-02-18 2005-02-18
PCT/GB2006/000548 WO2006087557A1 (en) 2005-02-18 2006-02-16 METHOD FOR DETERMINING RESPONSIVENESS TO CHKl INHIBITORS

Publications (1)

Publication Number Publication Date
NO20074610L true NO20074610L (no) 2007-11-14

Family

ID=36295309

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074610A NO20074610L (no) 2005-02-18 2007-09-11 Fremgangsmate for a bestemme mottakeligheten til CHK1 inhibitorer

Country Status (23)

Country Link
US (1) US20080145358A1 (no)
EP (1) EP1853721B1 (no)
JP (1) JP2008530575A (no)
KR (1) KR20070107034A (no)
CN (1) CN101120096A (no)
AT (1) ATE464395T1 (no)
AU (1) AU2006215413B2 (no)
BR (1) BRPI0607798A2 (no)
CA (1) CA2598185A1 (no)
CY (1) CY1110076T1 (no)
DE (1) DE602006013604D1 (no)
DK (1) DK1853721T3 (no)
ES (1) ES2341796T3 (no)
HR (1) HRP20100313T1 (no)
IL (1) IL184873A0 (no)
MX (1) MX2007010073A (no)
NO (1) NO20074610L (no)
NZ (1) NZ556718A (no)
PL (1) PL1853721T3 (no)
PT (1) PT1853721E (no)
SI (1) SI1853721T1 (no)
WO (1) WO2006087557A1 (no)
ZA (1) ZA200706670B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670097C (en) * 2006-11-21 2015-10-06 Merial Limited Prime boost canine leishmania vaccine
US8173366B2 (en) 2007-03-29 2012-05-08 University of Pittsburgh—of the Commonwealth System of Higher Education Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
US8263329B2 (en) 2007-03-29 2012-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
JP5436786B2 (ja) * 2008-03-06 2014-03-05 オリンパス株式会社 細胞周期計測方法
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
WO2016126616A1 (en) 2015-02-02 2016-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and kits for measuring and quantifying dna double-stranded breaks using gamma-h2ax and h2ax
AU2017261353A1 (en) * 2016-05-05 2018-11-08 Nantomics, Llc Checkpoint failure and methods therefor
WO2018030547A1 (ja) * 2016-08-12 2018-02-15 日立化成株式会社 血中循環癌細胞の検出方法及び血中循環癌細胞を検出するための前処理方法
US12429477B2 (en) * 2019-09-03 2025-09-30 The Council Of The Queensland Institute Of Medical Research Methods and agents for determining patient status
KR20250060189A (ko) 2022-07-13 2025-05-07 아크리본 테라퓨틱스 인코포레이티드 Atr/chk1 신호전달 경로 저해제를 사용하여 질환을 치료하는 방법 및 시스템

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001161398A (ja) * 1999-12-06 2001-06-19 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素の活性測定方法およびタンパク質リン酸化酵素の活性測定キット
OA13017A (en) * 2003-01-09 2006-11-10 Pfizer Diazepinoindole derivatives as kinase inhibitors.
AU2004220176A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
EP2664672A1 (en) * 2003-04-17 2013-11-20 Alnylam Pharmaceuticals Inc. Modified iRNA agents
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
US20050207998A1 (en) * 2003-07-21 2005-09-22 Yaoping Lu Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
CA2539320A1 (en) * 2003-09-17 2005-03-31 Icos Corporation Use of chk1 inhibitors to control cell proliferation

Also Published As

Publication number Publication date
IL184873A0 (en) 2007-12-03
DE602006013604D1 (de) 2010-05-27
ATE464395T1 (de) 2010-04-15
WO2006087557A1 (en) 2006-08-24
US20080145358A1 (en) 2008-06-19
HK1113059A1 (en) 2008-09-19
SI1853721T1 (sl) 2010-06-30
JP2008530575A (ja) 2008-08-07
DK1853721T3 (da) 2010-06-14
EP1853721B1 (en) 2010-04-14
ES2341796T3 (es) 2010-06-28
MX2007010073A (es) 2007-10-10
CY1110076T1 (el) 2015-01-14
AU2006215413A1 (en) 2006-08-24
HRP20100313T1 (hr) 2010-07-31
PL1853721T3 (pl) 2010-08-31
BRPI0607798A2 (pt) 2010-06-22
KR20070107034A (ko) 2007-11-06
CA2598185A1 (en) 2006-08-24
PT1853721E (pt) 2010-06-08
AU2006215413B2 (en) 2010-10-07
NZ556718A (en) 2010-10-29
CN101120096A (zh) 2008-02-06
EP1853721A1 (en) 2007-11-14
ZA200706670B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
NO20074610L (no) Fremgangsmate for a bestemme mottakeligheten til CHK1 inhibitorer
EP1984724A4 (en) DEVICE AND METHOD FOR QUANTITATING ANALYTES
ATE539165T1 (de) Verfahren zum nachweis von beta-lactamase
EP1810026A4 (en) B7-H1 AND METHOD FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER
EP3900615A3 (en) Detection meter and mode of operation
WO2010056337A3 (en) Methods and systems of using exosomes for determining phenotypes
DK1991697T3 (da) DNA-konformation (LOOP-strukturer) ved normal og anormal genekspression
WO2010067358A3 (en) Methods and kits for direct detection and susceptibility profiling of beta-lactam resistant bacteria
DK2046986T3 (da) Transkriptionsutroskab, detektion og anvendelse deraf
EP2084524A4 (en) MAGNETIC SENSOR ARRAY AND DEVICE DETECTION DEVICE USING THE MAGNETIC SENSOR ARRAY
EP1692102A4 (en) COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND SUFFERING RELATED TO CHEMOKIN RECEPTORS
EP2212700B8 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
EA201000734A1 (ru) Способ и аппарат для мониторинга пространственного образования фибринового сгустка
WO2005031005A3 (en) Compositions, methods and kits for determining the presence of trichomonas vaginalis in a test sample
GB2435328B (en) Methods and device for indirectly detecting the presence of an analyte
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
DK2185939T3 (da) Engangsanalyseudstyr med mikroprocessor
WO2006031644A3 (en) Immobilized probes and methods of detecting conformationally altered prion proteins
EP2585832A4 (en) REDUCTION OF INCORRECT RESULTS OF TEST MEASUREMENTS
EP1929044A4 (en) METHOD AND SAMPLE COMBINATIONS FOR MELANOMA DETECTION
EP2268800A4 (en) NEW IDENTIFIED HUMAN RHINOVIRUS OF TYPE HRV-C AND METHOD AND KITS FOR DETECTION OF TYPE HRV-CS
ATE333521T1 (de) Detektion von vancomycin-resistenten enterococcus-subspezies
WO2006124526A3 (en) Method for assessing the effectiveness of a treatment regimen by determining zonulin
FR2880426B1 (fr) Procede et dispositif pour la determination du point de fumee des hydrocarbures
EP2102393A4 (en) FOR PLATINATE COORDINATION COMPLEX-INDUCED OTOTOXICITY, PRE-DICTIVE POLYMORPHISMS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application